Patritumab
Patritumab is a humanized monoclonal antibody that targets the protein CD47. CD47 is a marker found on the surface of most cells in the body, including cancer cells. It helps these cells evade the immune system by interacting with the complement system and the scavenger receptor CD36. Patritumab is designed to bind to CD47 on the surface of cancer cells, preventing them from interacting with CD36 and allowing the immune system to recognize and attack the cancer cells.
The development of patritumab was driven by the need for more effective treatments for cancer, particularly
Patritumab is typically administered intravenously and is often used in combination with other therapies. It is
Patritumab is a promising treatment option for cancer patients, but like all medications, it has potential